What is it about?
Several studies have shown that nitric oxide (NO) and nitric oxide synthase (NOS) system plays an important role in carcinogenesis. Endothelial nitric oxide synthase (eNOS) gene polymorphisms significantly affects serum NO concentrations. Studies addressing the relationship between eNOS gene polymorphisms and prostate cancer (CaP) are very scarce. We examined the association between the 3 eNOS gene polymorphisms (T-786C, G894T, and 4a/b) with risk and clinical features of CaP. One hundred seventy patients with CaP (mean age 63.6 ± 12.4 years) and 340 age-matched healthy controls (mean age 64.9 ± 12.9 years) were recruited in this case-control study.
Photo by Richard Catabay on Unsplash
Why is it important?
Nitric oxide (NO) is generated from L-arginine by 3 nitric oxide synthase (NOS) isoenzymes: neuronal nitric oxide synthase (nNOS/NOS1), inducible nitric oxide synthase (iNOS/NOS2), and endothelial nitric oxide synthase (eNOS/NOS3). Cytogenetic and molecular studies have shown that human chromosome arm 7q contains a gene that may play an important role in the progression of the human prostate cancer (CaP). The human eNOS (NOS3) gene is located on chromosome 7q35–36 and contains 26 exons, and 3 polymorphisms in the eNOS gene have been widely studied.
Read the Original
This page is a summary of: Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer, Urologic Oncology Seminars and Original Investigations, October 2013, Elsevier, DOI: 10.1016/j.urolonc.2012.01.002.
You can read the full text:
The following have contributed to this page